A Phase 4 interventional study of Roflumilast and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 180 sites in 21 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-12-13.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.
Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 2nd largest by enrollment, is one of 5 that started in 2011, is one of 8 in phase 4, and was the 13th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 17 · Phase 4 8
First in 2003; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,945 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 154 across the 32 interventional studies. Of the 30 that completed or were terminated, 17 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 32 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 10th largest by enrollment of the 194 interventional ones that give a count, is one of 28 that started in 2011, is one of 19 in phase 4, and was the 93rd registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing roflumilast in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07795086Sidra AzizComparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed combination of long-acting β2-agonists (LABA) and inhaled glucocorticosteroids (ICS). In addition, data on safety and tolerability of roflumilast will be obtained. An additional objective is to further characterize the population pharmacokinetic profile of roflumilast and roflumilast N oxide and to further characterize their pharmacokinetics/pharmacodynamics (PK/PD) relationship in terms of efficacy and relevant safety aspects.
Patients to be included are required to have severe COPD associated with chronic bronchitis and a history of frequent exacerbations and must be concomitantly treated with a fixed combination of LABA and ICS. Two parallel treatment arms (roflumilast 500 μg once daily and placebo) are included.
The drug tested in this study is called Roflumilast. Roflumilast is being developed to treat people who have chronic obstructive pulmonary disease (COPD). This study investigated the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate, pulmonary function, and major adverse cardiovascular events (MACE) in COPD patients who were concomitantly treated with a fixed combination of long-acting beta-agonists (LABA) and inhaled glucocorticosteroids.
The study was targeted to enroll approximately 1934 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):
Trial treatment was taken in the morning by mouth after breakfast with some water.
The trial consisted of the following periods:
This multi-center trial was conducted worldwide. The overall time to participate in this study was up to 64 weeks. Participants made multiple visits to the clinic which included a follow-up visit at week 64.
Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
Drug: Roflumilast
concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
Drug: Placebo
500 µg, once daily
once daily
Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year
A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as follows: Severe=Requiring hospitalization and/or leading to death; Moderate=Requiring oral or parenteral glucocorticosteroid therapy. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.
Time frame: 52 weeks
Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First Second (FEV1)
Pulmonary function testing was performed using centralised spirometry. FEV1 is the maximum amount of air that can be forcefully exhaled in one second. Least-squares means is from Analysis of Covariance (ANCOVA) including treatment by time interaction. A positive change from Baseline indicates improvement.
Time frame: Baseline and Week 52
Rate of Severe COPD Exacerbations Per Patient Per Year
A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. Severe COPD exacerbations were categorized as requiring hospitalization and/or leading to death. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.
Time frame: 52 weeks
Rate of COPD Exacerbations Per Patient Per Year All Categories
A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as follows: Severe=Requiring hospitalization and/or leading to death; Moderate=Requiring oral or parenteral glucocorticosteroid therapy. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.
Time frame: 52 weeks
Percentage of Participants Experiencing at Least 1 COPD Exacerbation
A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.
Time frame: 52 weeks
Time to First COPD Exacerbation All Categories
Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day for all events: mild, moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.
Time frame: 52 Weeks
Time to Second Moderate or Severe COPD Exacerbation
Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day for events: moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.
Time frame: 52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)
Time to Third Moderate or Severe COPD Exacerbation
Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day for events: moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.
Time frame: 52 Weeks
Number of Patients Needed to Treat to Avoid 1 Moderate or Severe COPD Exacerbation Derived From Exacerbation Per Patient Per Year
The number needed to treat (NNT) analysis is a simple, concise method to quantify directly the benefits that alternative treatment options have on disease outcomes in terms of the number of patients who need to be treated before a benefit is observed. Risk reduction: Rate(Placebo)- Rate (Roflumilast 500 μg), Number needed to treat for benefit (NNTB): 1/(Risk reduction). A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.
Time frame: 52 Weeks
Number of Moderate or Severe COPD Exacerbation Days
A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. The number of exacerbation days per patient is the sum of durations (stop date of exacerbation - start date of exacerbation + 1) of all exacerbations within the category.
Time frame: 52 Weeks
Duration of Moderate or Severe COPD Exacerbations Per Participant
A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.
Time frame: 52 Weeks
Change From Baseline in Post-Bronchodilator Forced Vital Capacity (FVC)
Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Least-squares means was from ANCOVA including treatment by time interaction. A positive change from Baseline indicates improvement.
Time frame: 52 weeks
Change From Baseline in Post-Bronchodilator Forced Expiratory Flow at 25% to 75% of Vital Capacity (FEF25-75%)
Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry. Least-squares means was from ANCOVA including treatment by time interaction. A positive change from Baseline indicates improvement.
Time frame: 52 weeks
Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First 6 Seconds (FEV6)
FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first six seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry. A positive change from Baseline indicates improvement.
Time frame: 52 weeks
Change From Baseline in Post-Bronchodilator FEV1/FVC
The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry. A positive change from Baseline indicates improvement.
Time frame: 52 weeks
Change From Baseline in Use of Rescue Medication From Daily Diary
Salbutamol metered dose inhaler was available as rescue medication during the study. The participant recorded the use of rescue medication in a daily diary. A negative change from Baseline indicates an improvement.
Time frame: Baseline and Week 52
Change From Baseline in COPD Symptom Score From Daily Diary
Participants recorded COPD symptoms cough and sputum production in a daily diary. Cough was assessed using a 4-point scale where 0=No cough to 3=severe cough and sputum was assessed using a 4-point scale where 0=no sputum production to 3=severe sputum production. Least-squares means from ANCOVA including treatment by time interaction. A negative change from Baseline indicates improvement. Total symptom score is the sum of cough and sputum scores, ranging from 0 (best possible outcome) to 6 (worst possible outcome).
Time frame: 52 weeks
Percentage of Symptom-Free Days
Symptoms of COPD (cough, sputum) were recorded in a daily diary. The percentage of days without symptoms is reported.
Time frame: 52 Weeks
Percentage of Rescue Medication-Free Days
Participants recorded their use of rescue medication in a daily diary. The percentage of days without rescue medication use.
Time frame: 52 Weeks
Change From Baseline in COPD Assessment Test (CAT) Total Score
Participants completed the CAT questionnaire at Baseline and after 52 Weeks of Treatment. The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. A negative change from Baseline indicates improvement. Least-squares means from ANCOVA including treatment by time interaction.
Time frame: Baseline and Week 52
Percentage of Participants With Improvement in CAT
Participants completed the CAT questionnaire at Baseline and after 52 Weeks of treatment. The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. Improvement was defined as a CAT Total Score reduction from Baseline \> 1.6.
Time frame: Baseline and Week 52
Time to Mortality Due to Any Reason During the Treatment Period Score
Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.
Time frame: 52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)
Time to Mortality Due to COPD Exacerbation During the Treatment Period
Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.
Time frame: 52 Weeks
Time to Withdrawal During the Treatment Period
Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.
Time frame: 52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)
Time to Withdrawal Due to COPD Exacerbation During the Treatment Period
Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.
Time frame: 52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)
Percentage of Participants With Major Adverse Cardiovascular Event (MACE) During the Treatment Period
Composite MACE is a combined endpoint (cardiovascular death \[including death due to undetermined cause\], nonfatal myocardial infarction, and nonfatal stroke).
Time frame: 52 Weeks
Time to First Major Adverse Cardiovascular Event (MACE) During the Treatment Period
Composite MACE is a combined endpoint(cardiovascular death \[including death due to undetermined cause\], nonfatal myocardial infarction, and nonfatal stroke). Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.
Time frame: 52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)
Percentage of Participant With All-Cause Hospitalisation During the Treatment Period
Percentage of patients with at least one hospital admission due to any cause.
Time frame: 52 Weeks
Time to First Hospitalisation Due to Any Cause During the Treatment Period
Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.
Time frame: 52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)
Time to Trial Withdrawal Due to an Adverse Event
Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.
Time frame: 52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)
Percentage of Participants Who Experienced at Least 1 Treatment Emergent Adverse Event (TEAE)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: 52 Weeks
Change From Baseline in Body Weight
Least Square Means was from an ANCOVA model including Last Observation Carried Forward (LOCF).
Time frame: Baseline and Week 52
Change From Baseline in Body Mass Index (BMI)
Body mass index (BMI) is a measure of body fat based on height and weight. Least Square Means was from an ANCOVA model including LOCF.
Time frame: Baseline and Week 52
Participants took part in the study at 203 investigative sites in Australia, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Korea (Republic of), Netherlands, Poland, Russia, Slovak Republic, South Africa, Spain, Turkey and United Kingdom from 28 May 2011 to 27 May 2014.
| Milestone | Roflumilast 500 µg | Placebo |
|---|---|---|
| Started | 973 | 972 |
| Full analysis set (fas) | 969 | 966 |
| Safety population | 968 | 967 |
| Completed | 704 | 780 |
| Not completed | 269 | 192 |
| Withdrew: Withdrawal by subject | 117 | 87 |
| Withdrew: Adverse event | 82 | 29 |
| Withdrew: Death | 16 | 19 |
| Withdrew: Other | 14 | 20 |
| Withdrew: Copd exacerbation | 11 | 18 |
| Withdrew: Physician decision | 16 | 13 |
| Withdrew: Lost to follow-up | 8 | 5 |
| Withdrew: Met pre-defined discontinuation criteria | 5 | 1 |
A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as follows: Severe=Requiring hospitalization and/or leading to death; Moderate=Requiring oral or parenteral glucocorticosteroid therapy. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.
| exacerbations per patient per year | Roflumilast 500 µg | Placebo |
|---|---|---|
| Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year | 0.805 (0.724 to 0.895) | 0.927 (0.843 to 1.020) |
Pulmonary function testing was performed using centralised spirometry. FEV1 is the maximum amount of air that can be forcefully exhaled in one second. Least-squares means is from Analysis of Covariance (ANCOVA) including treatment by time interaction. A positive change from Baseline indicates improvement.
| liters | Roflumilast 500 µg | Placebo |
|---|---|---|
| Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First Second (FEV1) | 0.052 ± 0.0064 | -0.004 ± 0.0062 |
A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. Severe COPD exacerbations were categorized as requiring hospitalization and/or leading to death. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.
| exacerbations per patient per year | Roflumilast 500 µg | Placebo |
|---|---|---|
| Rate of Severe COPD Exacerbations Per Patient Per Year | 0.239 (0.201 to 0.283) | 0.315 (0.270 to 0.368) |
A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as follows: Severe=Requiring hospitalization and/or leading to death; Moderate=Requiring oral or parenteral glucocorticosteroid therapy. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.
| exacerbations per patient per year | Roflumilast 500 µg | Placebo |
|---|---|---|
| Moderate | 0.574 (0.508 to 0.648) | 0.627 (0.561 to 0.702) |
| Mild, Moderate or Severe | 3.078 (2.723 to 3.479) | 3.879 (3.492 to 4.310) |
| Leading to Hospitalisation | 0.238 (0.200 to 0.283) | 0.313 (0.268 to 0.365) |
| Glucocorticosteroids and/or Antibiotics treatment | 0.794 (0.716 to 0.88) | 0.929 (0.847 to 1.019) |
| Moderate or Severe and/or treated with Antibiotics | 1.012 (0.922 to 1.110) | 1.210 (1.115 to 1.313) |
A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.
| percentage of participants | Roflumilast 500 µg | Placebo |
|---|---|---|
| Percentage of Participants Experiencing at Least 1 COPD Exacerbation | 55.2 | 60.5 |
Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day for all events: mild, moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.
| days | Roflumilast 500 µg | Placebo |
|---|---|---|
| Time to First COPD Exacerbation All Categories | 218.0 (189.0 to 259.0) | 180.0 (147.0 to 200.0) |
Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day for events: moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.
| days | Roflumilast 500 µg | Placebo |
|---|---|---|
| Time to Second Moderate or Severe COPD Exacerbation | 421.0 (413.0 to NA) | NA (NA to NA) |
Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day for events: moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.
| days | Roflumilast 500 µg | Placebo |
|---|---|---|
| Time to Third Moderate or Severe COPD Exacerbation | NA (NA to NA) | NA (NA to NA) |
The number needed to treat (NNT) analysis is a simple, concise method to quantify directly the benefits that alternative treatment options have on disease outcomes in terms of the number of patients who need to be treated before a benefit is observed. Risk reduction: Rate(Placebo)- Rate (Roflumilast 500 μg), Number needed to treat for benefit (NNTB): 1/(Risk reduction). A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.
| participants | Roflumilast 500 µg | Placebo |
|---|---|---|
| Number of Patients Needed to Treat to Avoid 1 Moderate or Severe COPD Exacerbation Derived From Exacerbation Per Patient Per Year | 0.805 | 0.927 |
A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. The number of exacerbation days per patient is the sum of durations (stop date of exacerbation - start date of exacerbation + 1) of all exacerbations within the category.
| days | Roflumilast 500 µg | Placebo |
|---|---|---|
| Number of Moderate or Severe COPD Exacerbation Days | 26.9 ± 23.09 | 30.9 ± 29.49 |
A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.
| days | Roflumilast 500 µg | Placebo |
|---|---|---|
| Duration of Moderate or Severe COPD Exacerbations Per Participant | 15.9 ± 10.59 | 16.6 ± 14.49 |
Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Least-squares means was from ANCOVA including treatment by time interaction. A positive change from Baseline indicates improvement.
| liters | Roflumilast 500 µg | Placebo |
|---|---|---|
| Change From Baseline in Post-Bronchodilator Forced Vital Capacity (FVC) | 0.036 ± 0.0114 | -0.057 ± 0.0111 |
Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry. Least-squares means was from ANCOVA including treatment by time interaction. A positive change from Baseline indicates improvement.
| liters/second | Roflumilast 500 µg | Placebo |
|---|---|---|
| Change From Baseline in Post-Bronchodilator Forced Expiratory Flow at 25% to 75% of Vital Capacity (FEF25-75%) | 0.035 ± 0.0044 | 0.009 ± 0.0043 |
FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first six seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry. A positive change from Baseline indicates improvement.
| liters | Roflumilast 500 µg | Placebo |
|---|---|---|
| Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First 6 Seconds (FEV6) | 0.061 ± 0.0093 | -0.033 ± 0.0091 |
The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry. A positive change from Baseline indicates improvement.
| percent | Roflumilast 500 µg | Placebo |
|---|---|---|
| Change From Baseline in Post-Bronchodilator FEV1/FVC | 1.170 ± 7.0339 | 0.580 ± 6.8405 |
Salbutamol metered dose inhaler was available as rescue medication during the study. The participant recorded the use of rescue medication in a daily diary. A negative change from Baseline indicates an improvement.
| puffs per day | Roflumilast 500 µg | Placebo |
|---|---|---|
| Change From Baseline in Use of Rescue Medication From Daily Diary | -0.109 ± 0.0676 | 0.173 ± 0.0654 |
Participants recorded COPD symptoms cough and sputum production in a daily diary. Cough was assessed using a 4-point scale where 0=No cough to 3=severe cough and sputum was assessed using a 4-point scale where 0=no sputum production to 3=severe sputum production. Least-squares means from ANCOVA including treatment by time interaction. A negative change from Baseline indicates improvement. Total symptom score is the sum of cough and sputum scores, ranging from 0 (best possible outcome) to 6 (worst possible outcome).
| score on a scale | Roflumilast 500 µg | Placebo |
|---|---|---|
| Change From Baseline in COPD Symptom Score From Daily Diary | -0.412 ± 0.0315 | -0.398 ± 0.0306 |
Symptoms of COPD (cough, sputum) were recorded in a daily diary. The percentage of days without symptoms is reported.
| percentage of days | Roflumilast 500 µg | Placebo |
|---|---|---|
| Percentage of Symptom-Free Days | 7.09 ± 17.119 | 6.88 ± 16.185 |
Participants recorded their use of rescue medication in a daily diary. The percentage of days without rescue medication use.
| percentage of days | Roflumilast 500 µg | Placebo |
|---|---|---|
| Percentage of Rescue Medication-Free Days | 23.25 ± 33.734 | 22.77 ± 33.141 |
Participants completed the CAT questionnaire at Baseline and after 52 Weeks of Treatment. The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. A negative change from Baseline indicates improvement. Least-squares means from ANCOVA including treatment by time interaction.
| score on a scale | Roflumilast 500 µg | Placebo |
|---|---|---|
| Change From Baseline in COPD Assessment Test (CAT) Total Score | -1.270 ± 0.1556 | -0.985 ± 0.1518 |
Participants completed the CAT questionnaire at Baseline and after 52 Weeks of treatment. The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. Improvement was defined as a CAT Total Score reduction from Baseline \> 1.6.
| percentage of participants | Roflumilast 500 µg | Placebo |
|---|---|---|
| Percentage of Participants With Improvement in CAT | 71.2 | 72.5 |
Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.
| days | Roflumilast 500 µg | Placebo |
|---|---|---|
| Time to Mortality Due to Any Reason During the Treatment Period Score | NA (44 to 381) | NA (21 to 293) |
Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.
| days | Roflumilast 500 µg | Placebo |
|---|---|---|
| Time to Mortality Due to COPD Exacerbation During the Treatment Period | NA (44 to 322) | NA (25 to 293) |
Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.
| days | Roflumilast 500 µg | Placebo |
|---|---|---|
| Time to Withdrawal During the Treatment Period | 420.0 (5 to 428) | 444.0 (1 to 444) |
Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.
| days | Roflumilast 500 µg | Placebo |
|---|---|---|
| Time to Withdrawal Due to COPD Exacerbation During the Treatment Period | NA (25 to 371) | NA (12 to 319) |
Composite MACE is a combined endpoint (cardiovascular death \[including death due to undetermined cause\], nonfatal myocardial infarction, and nonfatal stroke).
| percentage of participants | Roflumilast 500 µg | Placebo |
|---|---|---|
| Percentage of Participants With Major Adverse Cardiovascular Event (MACE) During the Treatment Period | 1.7 | 1.7 |
Composite MACE is a combined endpoint(cardiovascular death \[including death due to undetermined cause\], nonfatal myocardial infarction, and nonfatal stroke). Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.
| days | Roflumilast 500 µg | Placebo |
|---|---|---|
| Time to First Major Adverse Cardiovascular Event (MACE) During the Treatment Period | NA (52 to 415) | NA (50 to 365) |
Percentage of patients with at least one hospital admission due to any cause.
| percentage of participants | Roflumilast 500 µg | Placebo |
|---|---|---|
| Percentage of Participant With All-Cause Hospitalisation During the Treatment Period | 24.9 | 29.3 |
Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.
| days | Roflumilast 500 µg | Placebo |
|---|---|---|
| Time to First Hospitalisation Due to Any Cause During the Treatment Period | 400.0 (387.0 to 415.0) | 408.0 (391.0 to 420.0) |
Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.
| days | Roflumilast 500 µg | Placebo |
|---|---|---|
| Time to Trial Withdrawal Due to an Adverse Event | NA (7 to 420) | NA (13 to 444) |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| percentage of participants | Roflumilast 500 µg | Placebo |
|---|---|---|
| Percentage of Participants Who Experienced at Least 1 Treatment Emergent Adverse Event (TEAE) | 66.9 | 59.2 |
Least Square Means was from an ANCOVA model including Last Observation Carried Forward (LOCF).
| kilogram (kg) | Roflumilast 500 µg | Placebo |
|---|---|---|
| Change From Baseline in Body Weight | -2.66 ± 0.130 | -0.14 ± 0.130 |
Body mass index (BMI) is a measure of body fat based on height and weight. Least Square Means was from an ANCOVA model including LOCF.
| kg/m^2 | Roflumilast 500 µg | Placebo |
|---|---|---|
| Change From Baseline in Body Mass Index (BMI) | -0.94 ± 0.046 | -0.04 ± 0.046 |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roflumilast 500 µg | — | 249/968 (25.7%) | 228/968 (23.6%) |
| Placebo | — | 285/967 (29.5%) | 114/967 (11.8%) |
| Event | Roflumilast 500 µg | Placebo |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 144/968 | 184/967 |
| PneumoniaInfections and infestations | 33/968 | 37/967 |
| Infective exacerbation of chronic obstructive airways diseaseInfections and infestations | 3/968 | 7/967 |
| Atrial fibrillationCardiac disorders | 6/968 | 6/967 |
| Angina pectorisCardiac disorders | 1/968 | 5/967 |
| Cardiac failureCardiac disorders | 3/968 | 5/967 |
| Myocardial infarctionCardiac disorders | 3/968 | 5/967 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 5/968 | 1/967 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/968 | 4/967 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/968 | 4/967 |
| Event | Roflumilast 500 µg | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 97/968 | 33/967 |
| Weight decreasedInvestigations | 84/968 | 27/967 |
| NauseaGastrointestinal disorders | 55/968 | 15/967 |
| NasopharyngitisInfections and infestations | 52/968 | 52/967 |
Full Analysis Set (FAS) includes all randomised participants who took at least 1 dose of investigational medicinal product (IMP) after randomisation.
| Age, Continuous(years) | Roflumilast 500 µg | Placebo | Total |
|---|---|---|---|
| Mean | 64.7 ± 8.38 | 64.7 ± 8.37 | 64.7 ± 8.37 |
| Age, Customized(participants) | Roflumilast 500 µg | Placebo | Total |
|---|---|---|---|
| ≤ 65 years | 527 | 542 | 1069 |
| > 65 years | 442 | 424 | 866 |
| Gender(Participants) | Roflumilast 500 µg | Placebo | Total |
|---|---|---|---|
| Female | 251 | 241 | 492 |
| Male | 718 | 725 | 1443 |
| Race/Ethnicity, Customized(participants) | Roflumilast 500 µg | Placebo | Total |
|---|---|---|---|
| Asian | 20 | 16 | 36 |
| Black or African American | 6 | 5 | 11 |
| White | 940 | 943 | 1883 |
| Other | 3 | 2 | 5 |
| Region of Enrollment(participants) | Roflumilast 500 µg | Placebo | Total |
|---|---|---|---|
| Australia | 9 | 16 | 25 |
| Austria | 11 | 3 | 14 |
| Belgium | 19 | 18 | 37 |
| Brazil | 42 | 38 | 80 |
| Canada | 14 | 12 | 26 |
| Denmark | 15 | 19 | 34 |
| France | 16 | 13 | 29 |
| Germany | 70 | 63 | 133 |
| Greece | 38 | 30 | 68 |
| Hungary | 111 | 125 | 236 |
| Israel | 114 | 126 | 240 |
| Italy | 64 | 51 | 115 |
| Korea, Republic Of | 11 | 7 | 18 |
| Netherlands | 11 | 8 | 19 |
| Poland | 88 | 88 | 176 |
| Russian Federation | 177 | 181 | 358 |
| Slovakia | 25 | 33 | 58 |
| South Africa | 23 | 30 | 53 |
| Spain | 37 | 33 | 70 |
| Turkey | 52 | 44 | 96 |
| United Kingdom | 22 | 28 | 50 |
| Height(cm) | Roflumilast 500 µg | Placebo | Total |
|---|---|---|---|
| Mean | 168.20 ± 8.652 | 168.33 ± 8.198 | 168.26 ± 8.427 |
| Weight(kg) | Roflumilast 500 µg | Placebo | Total |
|---|---|---|---|
| Mean | 75.07 ± 17.275 | 75.60 ± 17.238 | 75.33 ± 17.254 |
| Body Mass Index (BMI)(kg/m^2) | Roflumilast 500 µg | Placebo | Total |
|---|---|---|---|
| Mean | 26.45 ± 5.474 | 26.58 ± 5.359 | 26.52 ± 5.416 |
12 further baseline measures are reported on the registry.
Showing the first 100 of 180 sites across 21 countries. Choose a country and city above to see the rest.
The record gives a start of May 2011, a primary completion of Mar 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Pulmonary Disease, Chronic Obstructive →